Chronic rhinosinusitis with and without nasal polyps and asthma: Omalizumab improves residual anxiety but not depression
Abstract Background Chronic rhinosinusitis (CRS) has a high prevalence of anxiety and depression. It is currently uncertain if treatment in patients with CRS with or without nasal polyps (CRSwNP and CRSsNP) has any impact on improving mental health outcomes. The aims here were to document anxiety an...
Main Authors: | Florian Vogt, Jagdeep Sahota, Therese Bidder, Rebecca Livingston, Helene Bellas, Simon B. Gane, Valerie J. Lund, Douglas S. Robinson, Harsha H. Kariyawasam |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-03-01
|
Series: | Clinical and Translational Allergy |
Subjects: | |
Online Access: | https://doi.org/10.1002/clt2.12002 |
Similar Items
-
Chronic rhinosinusitis and omalizumab: eosinophils not IgE predict treatment response in real-life
by: Jagdeep Sahota, et al.
Published: (2018-10-01) -
Clinical effectiveness and potential predictability of omalizumab in patients with difficult-to-treat chronic rhinosinusitis with nasal polyps and asthma based on the noninvasive markers – A real-life prospective study
by: Ming Zheng, MD, PhD, et al.
Published: (2022-10-01) -
Revision surgery versus biologic treatment with omalizumab in recurrent chronic rhinosinusitis with nasal polyps: An analysis of cost-utility and clinical outcomes
by: Yutong Sima, MS, et al.
Published: (2023-12-01) -
Omalizumab and cancer risk: Current evidence in allergic asthma, chronic urticaria, and chronic rhinosinusitis with nasal polyps
by: Diego Bagnasco, MD, PhD, et al.
Published: (2022-12-01) -
Real-Life Effects of Omalizumab on Chronic Rhinosinusitis with Nasal Polyposis
by: Nicola Lombardo, et al.
Published: (2023-12-01)